版本:
中国

BRIEF-Can-Fite sees FY 2019 sales $1.4 billion

March 31 Can Fite Biopharma Ltd:

* Can Fite reports 2016 financial results & provides clinical update

* Sees FY 2019 sales $1.4 billion

* Can Fite Biopharma Ltd - Can Fite expects to be ready to commence its pivotal phase III acrobat trial of piclidenoson in Q2 of 2017

* Can Fite Biopharma Ltd - Psoriasis market is forecast to be $8.9 billion in 2018 and otezla® sales are estimated to be $2.35 billion by 2020

* Can Fite Biopharma Ltd - liver cancer drugs are expected to generate $1.4 billion in sales in 2019

* Can Fite Biopharma Ltd - by 2025, addressable pharmaceutical market for NASH is estimated to reach $35-40 billion Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐